Get to know our clinical trials
Trial of blyg8824a administered intravenously as monotherapy in patients with locally advanced or metastatic colorectal cancer.
THE AIM OF THIS STUDY IS TO EVALUATE BLYG8824A AT DIFFERENT DOSES TO DETERMINE IF IT IS SAFE, FIND OUT HOW THE BODY PROCESSES THE DRUG, AND DETERMINE THE EFFECTS, POSITIVE OR NEGATIVE, THAT BLYG8824A HAS ON YOU AND YOUR CANCER.
- PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER
- Code EudraCT: 2019-004874-24
- Protocol number: GO41751
- Promoter: Genentech, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.